<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723382</url>
  </required_header>
  <id_info>
    <org_study_id>ESS015000</org_study_id>
    <nct_id>NCT03723382</nct_id>
  </id_info>
  <brief_title>Stroke in Egyptian Clinical REgisTry</brief_title>
  <acronym>SECRET</acronym>
  <official_title>Stroke in Egyptian Clinical REgisTry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Society of Minimally Invasive Neurological Therapeutic Procedures</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Egyptian Stroke Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Egyptian Society of Neurological Surgeons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Egyptian Radiology Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Middle East North Africa Stroke and Interventional Neurotherapies Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Society of Minimally Invasive Neurological Therapeutic Procedures</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institutional registry database for the patients with stroke and
      cerebrovascular diseases. Stroke is the second leading cause of death in the Egypt. Despite
      extensive research, most of the patients die or suffer from varying degree of post-stroke
      disabilities due to neurologic deficits.

      This registry aims to understand the disease and examine the disease dynamics at the National
      Level. additionally it aim to introduce an objective method for classifying the registered
      hospital on a spectrum of 6 level coded with colors (from Black to Green ) according the
      availability of the predetermined 5 bundles of services presented for patient
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A clinical registry is an observational database, usually focusing on a clinical condition,
      procedure, therapy, or population. A stroke registry can be defined as &quot;an organized system
      for the collection, storage, retrieval, analysis, and dissemination of information on
      individual patients who have had a stroke&quot;.

      An ideal stroke registry is nationwide and enrolls patients from as many participating
      hospitals as possible in order to increase representativeness and avoid selection bias. For
      example, the Risk-Stroke register in Sweden, launched in 1994, has covered all hospitals that
      admit acute stroke patients across the country since 1998 . Appropriate data structure and
      governance policies are needed to keep a nationwide stroke registry sustainable and operating
      well. Through the publication and communication of results, a stroke registry should be
      helpful for improvement of stroke care quality, health policy, and the outcomes of patients.

      SECRET registry aim to help in the following

        1. National Grading of The Presented Stroke Care Services:

           where A 6 levels grading system was designed according to the capability of each service
           spot (hospital, center, etc.) to present a range of the 5 stroke service bundles of
           care. each Service Spot (SS) will have one of the following colors according to the
           availability of the services.

        2. Cost-effectiveness registry Based SOPs SECRET is the first of its type registry to study
           the parameters for cost/effectiveness analysis for specific steps in the chain of care
           for stroke patient. The only convincing tool which could be used to approach the
           politics to be attentive and malleable for changing national plans of healthcare.

        3. Aneurysm Registry This Part of the registry is dedicated for the cerebral aneurysm
           disorders and their type of clinical presentation. The options of treatment and each
           option effectiveness and cost outcome.

      CFD for Best Medical Treatment Registry To investigate the possible application collected
      from CFD analysis in special situation to guide physician for best medical treatment (BMT)
      option for a Neurovascular Disorder.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The National Institutes of Health Stroke Scale (NIHSS) reported</measure>
    <time_frame>30 days post discharge from hospital</time_frame>
    <description>Severity of ischemic stroke and stroke not otherwise specified patients will be weighted with a score reported for NIH Stroke Scale will be grouped into Mild stroke (&gt;0-6 on NIHSS) moderate (&gt;6 - 10 on NIHSS) severe (&gt;10 - 20 on NIHSS) and Grave (&gt;20 on NIHSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Rankin Scale at Discharge</measure>
    <time_frame>90 days post discharge from hospital</time_frame>
    <description>Patients grouped by Modified Rankin Scale at discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk-Adjusted Mortality Ratio for Ischemic-Only and Ischemic and Hemorrhagic models</measure>
    <time_frame>30 days post discharge from hospital</time_frame>
    <description>A ratio comparing the actual in-hospital mortality rate to the risk-adjusted expected mortality rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease burden</measure>
    <time_frame>1 year</time_frame>
    <description>Quality-Adjusted Life-Years (QALY) : measure of the life expectancy corrected for loss of quality of that life caused by diseases and disabilities.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Stroke, Cardiovascular</condition>
  <condition>Stroke, Acute</condition>
  <condition>Stroke Hemorrhagic</condition>
  <condition>Stroke Spinal Cord</condition>
  <condition>Stroke, Complication</condition>
  <arm_group>
    <arm_group_label>Patients with stroke with structured management</arm_group_label>
    <description>Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with stroke without structured management</arm_group_label>
    <description>Control subject who have stroke and did not managed according to the SECRET 6 level metrics</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SECRET structured 5 bundles of standard healthcare services</intervention_name>
    <description>THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach</description>
    <arm_group_label>Patients with stroke with structured management</arm_group_label>
    <other_name>Iv-Thrombolysis</other_name>
    <other_name>Endovascular treatment</other_name>
    <other_name>Rehabilitation , mobilization , bulbar care, secondary prevention</other_name>
    <other_name>Stroke unit calibration</other_name>
    <other_name>Prehospital care organization</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a final/discharge diagnosis of stroke or transient ischemic attack can be
        included into the SECRET Registry.

        This includes cases with a principal/primary or secondary diagnosis of:

        Cerebral Infarction Intracerebral Hemorrhage (non-traumatic) Ischemic Stroke Subarachnoid
        Hemorrhage (non-traumatic) Transient Ischemic Attack (TIA) Cerebral Venous Sinus Thrombosis
        The investigators will use the available EMR and databases to search for these patients
        using relevant ICD-9/10 codes. or any other method used internally to archive stroke cases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with a diagnosis of Acute Brain injury, Transient Ischemic Attack, Acute
             and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral
             venous thrombosis seen in the registered Centers.

          -  Age &gt; 1 years of age.

        Exclusion Criteria:

          -  Patients who don't have the diagnosis of Acute Brain injury, Transient Ischemic
             Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage,
             and cerebral venous thrombosis.

          -  Patients who have Epidural Hematoma, Subdural hematoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandria University , School of medicine , Neurology Department, Neurovascular Unit</name>
      <address>
        <city>Alexandria</city>
        <zip>22121</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ossama Mansour, MD,PhD,FNR</last_name>
      <phone>01223926932</phone>
      <email>yassinossama@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ashraf Abdo, MD,PhD,FNR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ismail Ramadan, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amro ElFatatry, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saher Hashim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Azza Ghali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eman Khedr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aymen Nassif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khalid Sobh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fathi afifi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tarek Meniece, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh Saeed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hazem Marouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hany Eldeeb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farouk Talaat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Abdallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khalid Marouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sayed Tag eldeen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farouk Hassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Elserwi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamer Hassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Khalid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hany Zakieldeen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mostafa Mahmoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amero Mahmoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Alaa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Aboelhassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Islam Ismail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Islam El-malki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed El-nemr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Islam El-desoky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ossama Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abeer Bekheet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael elshawaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.strokesregistry.com</url>
    <description>registry website</description>
  </link>
  <link>
    <url>http://www.egyptianstrokenetwork.com</url>
    <description>Egyptian Stroke Network -Alexandria Prototype</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Prof. Ossama Mansour</investigator_full_name>
    <investigator_title>Prof of neurology alexandria university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>once start for 7 years</ipd_time_frame>
    <ipd_access_criteria>registred user to Site Data Non registered User to Stat Data</ipd_access_criteria>
    <ipd_url>http://www.strokeregistry.eg</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>StateData001</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.strokesregistry.com/data-in-graphs/</doc_url>
      <doc_comment>These are measures for national stroke measures in State Pool of data</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

